Cancer Advocate and Taylor Swift Fan Emily Beazley, 12, Has Died

The four-year struggle against T-cell lymphoblastic non-Hodgkin's lymphoma is, sadly, over, for 12-year-old Emily Beazley of Chicago, who passed away on Monday, according to her mother.

Just last month, the beautiful young girl made headlines after her friends began a social media campaign-- which included a music video-- to convince Emily's idol, pop superstar Taylor Swift, to call her for a chat.

Swift--famous and beloved for such gestures--obliged.

“She knew all about me,” Beazley gushed to the Chicago Tribune last month. "She told me about her tour starting in Tokyo, she asked what my favorite song was, and I told her ‘Shake It Off.’ Then she said, ‘Oh, cool.’”

Beazley also recently threw out a first pitch for the Chicago White Sox, further proof of just how much this young girl touched her community.

First diagnosed at the age of eight, she looked for ways to to help kids like her in similarly difficult situations. That included making a video a couple of years ago with Advocate Children’s Hospital in Oak Lawn, Ill., in an effort to encourage other kids battling cancer to fight and to have hope.

"Even though she knew it was too late for her, she wanted people to continue to raise money for research," said Dr. Jason Canner. "She wanted to help find a cure."

Source: US Magazine

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap